1357089-50-9

Upstream product

• 60336-03-0 5-(4-chlorophenyl)furan-2-carboxylic acid ethyl ester 
• 41019-45-8 5-(4-chlorophenyl)-2-furoic acid 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 1357089-48-5 C₃₂H₃₀ClN₃O₈ 
• 1312579-02-4 C₁₉H₁₉N₃O₅ 

Downstream Products

• 1312579-06-8 C₃₀H₂₆ClN₃O₄ 
• 1312578-75-8 C₂₂H₂₀ClN₃O₂ 
• 1357089-39-4 C₂₄H₂₁ClN₄O 
• 1357089-41-8 C₂₃H₂₀ClN₅O 
• 1357089-44-1 C₂₅H₂₃ClN₄O 
• 1357089-45-2 C₂₄H₂₂ClN₅O 
• 1312579-07-9 C₃₇H₃₁BrClN₃O₄ 
• 1312579-08-0 C₄₂H₃₅ClN₄O₄ 
• 1312578-79-2 C₃₄H₂₉ClN₄O₂ 
• 1312578-93-0 C₃₅H₃₁ClN₄O₃ 
• 1312578-86-1 C₃₄H₂₉ClN₄O₂ 
• 1312578-78-1 C₂₃H₂₂ClN₃O₂ 
• 1312578-83-8 C₃₃H₂₈ClN₅O₂ 
• 1435946-84-1 C₂₅H₂₄ClN₃O₂ 

Relevant academic research and scientific papers

Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors

Facile synthesis of two new series of tetracyclic azepine and oxazocine analogs is described. These analogs were evaluated for their potential as MAPKAP-K2 (MK2) inhibitors and several were found to be potent at inhibiting MK2 with a non-ATP competitive binding mode.

FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.